Alex Herrera, MD, City of Hope Cancer Center, discusses patients’ reaction in the phase I/II trial of combination nivolumab/brentuximab vedotin in the second-line for patients with Hodgkin lymphoma.

Herrera emphasizes monitoring for infusion-related reactions when treating patients taking these two drugs together. There was an increased rate of these reactions in the study. However, the infusion-related reactions seen were mostly mild and were able to be treated with the standard supportive therapies. After treatment, the patients were able to resume infusion as normal.

Videos

Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.

Alex Herrera, MD

Articles

Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin Lymphoma